Investigators compared recurrence-free survival and overall survival outcomes in patients randomly assigned to receive neoadjuvant talimogene laherparepvec (T-VEC) followed by immediate surgery or surgery alone.
The approval was based on data from 2 multicenter, randomized, double-blind, phase 3 trials that evaluated the efficacy and safety of Klisyri ointment in adults with AK on the face or scalp.
In adolescents and young adults (AYAs), cancer has a unique epidemiological pattern and is a growing concern, with an increased rate of cancer from 1973 to 2015.
An algorithm that combines deep learning on histology slides and patient clinical data may predict immune checkpoint inhibitor response in patients with advanced melanoma.
